A study of a new medicine (fazpilodemab) in people with a type of liver disease called non-alcoholic steatohepatitis or NASH
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
- Metabolic Disorder
- Non Alcoholic Steato-Hepatitis
- Kidney Disorder
- Chronic Kidney Disease
Terminated
- Belgium
- France
- Puerto Rico
- Spain
- United States
NCT04171765 GC41033
Trial Summary
This study will evaluate the efficacy, safety, and pharmacokinetics of BFKB8488A compared to placebo in participants with non-alcoholic steatohepatitis (NASH).
A Phase II, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Patients With Non-Alcoholic Steatohepatitis
Eligibility Criteria
- Confirmed diagnosis of NASH as documented through liver biopsy performed no more than 6 months before randomization, defined according to NASH CRN criteria along with a NASH CRN fibrosis score between F2 and F3
- Hepatic steatosis on MRI (>= 8% average PDFF) prior to randomization
- History of any liver disease other than NASH, except for resolved, self-limited illnesses such as Hepatitis A or E, and previous Hepatitis C
- Weight gain > 10% or loss > 5% within 3 months prior to randomization
- History of liver transplantation
- Current or history of significant alcohol consumption
For the latest version of this information please go to www.forpatients.roche.com